Clinical Trials Logo

Clinical Trial Summary

The researchers are doing this study to provide access to treatment with 131I-omburtamab for children and young adults who have CNS/leptomeningeal neoplasms. 131I-omburtamab is an investigational drug; the FDA has not approved it to treat this cancer or any other disease. However, the agency has granted the drug Breakthrough Therapy Designation for the treatment of neuroblastoma with CNS metastases.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05064306
Study type Expanded Access
Source Memorial Sloan Kettering Cancer Center
Contact Sameer Farouk Sait, MD
Phone 833-675-5437
Email [email protected]
Status Available